Quarterly and annual results disclosed under 8-K Item 2.02.
Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.”
Omada Health, Inc. reported the full year ended December 31, 2025 results: revenue $260 million, net income net loss of $13 million.
“and full year 2025, except where otherwise noted. Total members • 886,000 at year end, up 55% year over year Revenue • $76 million in the fourth quarter, up 58% year over year • $260 million for the full year, up 53% compared with 2024 GLP-1 Leadership • Omada has now supported more than 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024 •”
Omada Health, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $76 million, net income $5 million.
“Revenue • $76 million in the fourth quarter, up 58% year over year • $260 million for the full year, up 53% compared with 2024”
Caribou Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $11.2 million, net income net loss of $148.1 million, EPS $1.59 per share.
“Fourth quarter and full year 2025 financial results Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.9 million for the three months ended December 31, 2025 and $11.2 million for full year 2025, compared to $2.1 million and $10.0 million, respectively, for the same periods in 2024. The increase for full year 2025 was primarily driven by a net increase in revenues related to prior licenses of certain of Caribou's intellectual property to third parties. R&D expenses: Research and development expenses were $23.8 million for the three months ended December 31, 2025 and $109.4 million for full year 2025, compared to $30.5 million, and $130.2 million respectively, for the same periods in 2024. The decrease for full year 2025 was primarily due to lower R&D and personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization, external contract manufacturing and contract research organization activitie”
Caribou Biosciences, Inc. reported the three months ended December 31, 2025 results: revenue $3.9 million, net income net loss of $26.5 million, EPS $0.28 per share.
“Fourth quarter and full year 2025 financial results Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.9 million for the three months ended December 31, 2025 and $11.2 million for full year 2025, compared to $2.1 million and $10.0 million, respectively, for the same periods in 2024. The increase for full year 2025 was primarily driven by a net increase in revenues related to prior licenses of certain of Caribou's intellectual property to third parties. R&D expenses: Research and development expenses were $23.8 million for the three months ended December 31, 2025 and $109.4 million for full year 2025, compared to $30.5 million, and $130.2 million respectively, for the same periods in 2024. The decrease for full year 2025 was primarily due to lower R&D and personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization, external contract manufacturing and contract research organization activitie”
Profound Medical Corp. reported the fourth quarter and full year ended December 31, 2025 results: revenue $6.0 million.
“Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million.”
CPI Card Group Inc. reported the full year ended December 31, 2025 results: revenue $543.5 million, net income $15.0 million. Guidance initiated.
“For the full year, revenue increased 13% to $543.5 million, driven by Arroweye, contactless cards, and instant issuance solutions. Net income was impacted by acquisition and integration costs and decreased 23% to $15.0 million, while Adjusted EBITDA increased 5% to $96.5 million.”
CPI Card Group Inc. reported the quarter ended December 31, 2025 results: revenue $153.1 million, net income $7.4 million. Guidance initiated.
“CPI’s fourth quarter revenue increased 22% to $153.1 million, driven by the addition of Arroweye and increased sales of contactless cards. Net income in the quarter increased 9% to $7.4 million and Adjusted EBITDA increased 34% to $29.4 million.”
Samsara Inc. reported fiscal quarter ended January 31, 2026 results: revenue $444.3 million, EPS $0.04.
“Q4 revenue of $444.3 million, representing 28% year-over-year growth in actuals and 27% in constant currency • Q4 net new ARR of $144.8 million representing 33% year-over-year growth in actuals and 31% in constant currency • Ending ARR of $1.890 billion, representing 30% year-over-year growth in actuals and in constant currency • GAAP earnings per share of $0.04, representing the second consecutive quarter of GAAP profitability”
NextCure, Inc. reported the full year ended December 31, 2025 results: net income Net loss was $55.8 million.
“NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December31, 2025.”
Bioventus Inc. reported Year ended December 31, 2025 results: revenue $568.1 million, net income $22.7 million, EPS $0.33.
“Full-Year 2025 Financial Results Bioventus’ full-year 2025 worldwide revenue totaled $568.1 million, a decrease of 0.9% compared to the prior-year period due to the divestiture of the Advanced Rehabilitation Business. On an organic* basis, revenue increased 7.5%, driven by above-market growth across all three businesses in the Company's portfolio. Full-year 2025 net income attributable to Bioventus was $22.7 million, compared to net loss attributable to Bioventus Inc. of $36.1 million in the prior-year period. Adjusted EBITDA* of $116.3 million increased 6.8% from $108.9 million last year due to strong organic* revenue growth and gross margin expansion. GAAP earnings of $0.33 per diluted share of Class A common stock improved from a loss of $0.56 per diluted share last year. Adjusted earnings per diluted share* was $0.68, reflecting a 21.4% increase compared to $0.56* * per diluted share in the prior-year period.”
Bioventus Inc. reported Three months ended December 31, 2025 results: revenue $157.9 million, net income $14.8 million, EPS $0.21.
“For the fourth quarter, worldwide revenue totaled $157.9 million, advancing 10.0% on an organic* basis driven by double-digit organic* growth across Pain Treatments and Surgical Solutions. Reported revenue increased 2.8% from $153.6 million in the prior-year period due to the impact of the prior-year divestiture of the Advanced Rehabilitation Business. Net income attributable to Bioventus Inc. was $14.8 million, compared to net loss attributable to Bioventus Inc. of $0.4 million in the prior-year period. Adjusted EBITDA* of $36.7 million advanced 30% from $28.3 million in the prior-year period as a result of higher organic* revenue growth, increased gross margin and disciplined spending. GAAP earnings of $0.21 per diluted share of Class A common stock improved from no income per share in the prior-year period. Adjusted Earnings Per Share (Adjusted EPS)* of Class A common stock of $0.24 per diluted share compares to $0.26** per diluted share in the prior-year period as improved operatin”
Shattuck Labs, Inc. reported financial results for the year ended December 31, 2025.
“On March 5, 2026, Shattuck Labs, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
Ranger Energy Services, Inc. reported the fiscal year ended December 31, 2025 results: revenue $546.9 million, net income $12.3 million, EPS $0.54 per diluted share.
“Full year 2025 revenue of $546.9 million and net income of $12.3 million, or $0.54 per diluted share”
Ranger Energy Services, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $142.2 million.
“Fourth quarter 2025 revenue of $142.2 million”
Ranpak Holdings Corp. reported 2026 results: revenue $415 – $445 million. Guidance initiated.
“We are forecasting net revenue growth in the area of 5.1% – 12.7% and AEBITDA growth of 5.4% – 19.9% compared to actual net revenue and AEBITDA for fiscal 2025, which results in a range of $415 – $445 million in net revenue and $83.5 – $95 million for AEBITDA.”
Ranpak Holdings Corp. reported the fourth quarter ended December 31, 2025 results: revenue $111.9 million, net income $9.5 million.
“Ranpak Holdings Corp. Reports Fourth Quarter and Full Year 2025 Financial Results • Net revenue for the fourth quarter increased 6.6% year over year to $111.9 million and increased 2.2% year over year on a constant currency basis • Net loss for the fourth quarter of $9.5 million compared to net loss of $8.0 million for the prior year period”
Red Violet, Inc. reported the year ended December 31, 2025 results: revenue $90.3 million, net income $13.2 million, EPS $0.94 and $0.91 per basic and diluted share.
“For the year ended December 31, 2025 as compared to the year ended December 31, 2024: • Total revenue increased 20% to $90.3 million. • Gross profit increased 26% to $65.1 million. Gross margin increased to 72% from 69%. • Adjusted gross profit increased 23% to $75.4 million. Adjusted gross margin increased to 84% from 81%. • Net income increased 88% to $13.2 million, which resulted in earnings of $0.94 and $0.91 per basic and diluted share, respectively. Net income margin increased to 15% from 9%.”
Red Violet, Inc. reported the three months ended December 31, 2025 results: revenue $23.4 million, net income $2.8 million, EPS $0.20 and $0.19 per basic and diluted share.
“For the three months ended December 31, 2025 as compared to the three months ended December 31, 2024: • Total revenue increased 20% to $23.4 million. • Gross profit increased 23% to $16.8 million. Gross margin increased to 72% from 70%. • Adjusted gross profit increased 21% to $19.5 million. Adjusted gross margin increased to 83% from 82%. • Net income increased 226% to $2.8 million, which resulted in earnings of $0.20 and $0.19 per basic and diluted share, respectively. Net income margin increased to 12% from 4%.”
Camp4 Therapeutics Corp reported the year ended December 31, 2025 results: net income $80.4 million.
“Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024.”
Compass Therapeutics, Inc. reported year ended December 31, 2025 results: net income $66.5 million, EPS $0.42 per common share.
“Net loss for the year ended December 31, 2025, was $66.5 million or $0.42 per common share”
GRID DYNAMICS HOLDINGS, INC. reported year ended December 31, 2025 results: revenue $411.8 million, net income $9.7 million, EPS $0.11 per share.
“Total revenues were $411.8 million, an increase of 17.5% year-over-year. • GAAP gross profit was $142.3 million, or 34.6% of revenues, compared to $127.0 million, or 36.2% of revenues, in 2024. • Non-GAAP gross profit was $144.5 million, or 35.1% of revenues, compared to $129.1 million, or 36.8% of revenues, in 2024. • GAAP net income was $9.7 million, or $0.11 per share, based on 86.9 million diluted weighted-average common shares outstanding, compared to $4.0 million, or $0.05 per share, based on 80.0 million diluted weighted-average common shares outstanding, in 2024.”
GRID DYNAMICS HOLDINGS, INC. reported quarter ended December 31, 2025 results: revenue $106.2 million, net income $0.3 million, EPS $0.00 per share.
“Total revenues were $106.2 million, an increase of 1.9% and 5.9% on a sequential and year-over-year basis, respectively. • GAAP gross profit was $36.1 million, or 34.0% of revenues, in the fourth quarter of 2025, compared to $37.0 million, or 36.9% of revenues, in the prior year corresponding period. • Non-GAAP gross profit was $36.6 million, or 34.5% of revenues, in the fourth quarter of 2025, compared to $37.6 million, or 37.5% of revenues, in the fourth quarter of 2024. • GAAP net income was $0.3 million, or $0.00 per share, based on 86.4 million diluted weighted-average common shares outstanding, in the fourth quarter of 2025, compared to $4.5 million, or $0.05 per share, based on 83.8 million diluted weighted-average common shares outstanding, in the fourth quarter of 2024.”
AerSale Corp reported financial results for the fiscal quarter and year ended December 31, 2025.
“On March 5, 2026, AerSale Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025.”
Climb Bio, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.”
Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.
“On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates.”
Aligos Therapeutics, Inc. reported the fourth quarter and full year 2025 results: net income Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share o, EPS $(1.91).
“Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share of $(1.91), compared to net loss of $82.2 million or basic and diluted net loss per common share of $(13.08) for the three months ended December 31, 2024.”
Enhabit, Inc. reported the quarter and year ended December 31, 2025 results: revenue $270.4 million.
“us to further strengthen our balance sheet, positioning us well to accelerate growth and investment in 2026.” QUARTERLY PERFORMANCE - CONSOLIDATED • Net service revenue of $270.4 million • Net loss attributable to Enhabit, Inc. of $38.7 million • Adjusted EBITDA of $28.0 million • Diluted loss per share of $0.76 • Adjusted diluted earnings per share of $0.14”
Pattern Group Inc. reported full year ended December 31, 2025 results: revenue $2.5 billion, net income $16 million.
“Fourth Quarter and Full Year 2025 Financial Results; Announces $100 Million Share Repurchase Program Delivered Full Year Revenue Growth of 39% Year over Year, for a Record $2.5 billion Delivered Record NRR of 124%, up from 116% in the Prior Year Pattern’s Board of Directors authorized repurchase program of up to $100 million of Series A common stock LEHI, UT —”
Pattern Group Inc. reported quarter ended December 31, 2025 results: revenue $723 million, net income $29 million, EPS $0.16.
“that our economics are directly tied to product sales, which aligns our success with that of our brand partners.” Fourth Quarter 2025 Financial Highlights • Record Revenues of $723 million, up 40% year over year. • Record Net Revenue Retention (“NRR”) of 124%, up from 116% in the prior year. • Record Revenue, not attributable to Amazon, of $61 million, up 94% year”
Owlet, Inc. reported full year 2026 results: revenue $126 to $130 million. Guidance initiated.
“For the full year 2026, we expect revenue in the range of $126 to $130 million, representing 19% to 23% growth over 2025, gross margins of 49% to 52% including the impact of tariff costs, and adjusted EBITDA of $3 to $5 million, representing 50% to 150% growth over 2025.”
Owlet, Inc. reported first quarter of 2026 results: revenue $20 to $21 million. Guidance initiated.
“For the first quarter of 2026, we expect revenue in the range of $20 to $21 million, gross margins of 50% to 52%, and adjusted EBITDA of $(2.5) to $(1.5) million.”
Owlet, Inc. reported year ended December 31, 2025 results: revenue $105.7 million, net income Net loss was $39.7 million for the fiscal year 2025, compared to net loss of $12.5 million for the fiscal year 2024., EPS Net loss per share was $2.31 for the fiscal year 2025, compared to net loss per share of $1.57 for the fiscal year 2024..
“For fiscal year 2025, revenue was $105.7 million, compared to $78.1 million for fiscal year 2024, an increase of 35.4%.”
Owlet, Inc. reported three months ended December 31, 2025 results: revenue $26.6 million, net income net loss of $9.2 million.
“Revenue for the fourth quarter of 2025 was $26.6 million, compared to revenue in the fourth quarter of 2024 of $20.5 million, an increase of 29.6%.”
Tango Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“Collaboration revenue was $0 for the three months ended December 31, 2025, compared to $5.4 million for the same period in 2024, and $62.4 million for the twelve months ended December 31, 2025, compared to $30.0 million for the same period in 2024.”
ESS Tech, Inc. reported year ended December 31, 2025 results: revenue $1.6 million, net income Net loss for the year ended December 31, 2025, was $63.4 million.
“Revenue was $1.6 million for the year ended December 31, 2025. The company’s business has been focused on the development and commercialization of its LDES systems. ◦ ESS delivered and recognized revenue from completed and in-process Energy Warehouses and Energy Centers (plus related equipment), engineering services for a site deployment, and extended warranty services, primarily offset by revenue reductions tied to settling and winding down legacy contracts as the Company shifted to the Energy Base offering and by lower overall sales volumes year over year. • Net loss for the year ended December 31, 2025, was $63.4 million”
Liquidia Corp reported fourth quarter of 2025 results: revenue $90.1 million, net income net income of $14.6 million.
“Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update · Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter · More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 · Ended 2025 with $190.7 million in cash and”
Liquidia Corp reported the year ended December 31, 2025 results: revenue $148.3 million, net income net loss of $68.9 million, EPS $0.80 per basic and diluted share.
“99.1 Exhibit 99.1 Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update · Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter · More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 ·”
TriSalus Life Sciences, Inc. reported 2026 results: revenue $60 million to $62 million. Guidance reaffirmed.
“Reaffirms 2026 Revenue Guidance of $60-62 million”
TriSalus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $45.2 million, net income $69.7 million, EPS $1.84.
“Revenue, all from sales of the TriNav system, was $45.2 million for the year ended December 31, 2025, an increase of 53% compared to the same period in 2024.”
TriSalus Life Sciences, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $13.2 million.
“Generated $13.2 million in net sales, a 60% increase year-over-year”
Palladyne AI Corp. reported full year 2026 results: revenue $24 million to $27 million. Guidance reaffirmed.
“The Company reiterates its previously announced full year 2026 revenue guidance of $24 million to $27 million, representing expected year-over-year growth of approximately 357% to 415% compared to 2025 revenue of $5.2 million.”
Palladyne AI Corp. reported the fiscal year ended December 31, 2025 results: revenue $5.2 million, net income $10.0 million, EPS $0.24.
“Full Year 2025 Financial Highlights (vs. full year 2024) • Revenue decreased 33% to $5.2 million compared to $7.8 million; • Operating loss of ($32.4) million compared to ($26.9) million; • GAAP net income and diluted EPS of $10.0 million, and $0.24, compared to a net loss of ($72.6) million, and ($2.71);”
Palladyne AI Corp. reported the fourth quarter ended December 31, 2025 results: revenue $1.7 million, net income ($1.5) million, EPS ($0.04).
“Fourth Quarter 2025 Financial Highlights (vs. fourth quarter 2024) • Revenue increased 118% to $1.7 million compared to $0.8 million; • Operating loss of ($9.3) million compared to ($6.5) million; • GAAP net loss and basic and diluted loss per share (EPS) of ($1.5) million, and ($0.04), compared to ($53.0) million, and ($1.75);”
FTC Solar, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $32.9 million, net income $33,734, EPS $(2.23).
“(EX-99.1) --- EX-99.1 Exhibit 99.1 FTC Solar Announces Fourth Quarter 2025 Financial Results Fourth Quarter Highlights and Recent Developments • Fourth quarter revenue of $32.9 million, up 26% q/q, 148.9% y/y, in line with target guidance • Gross margin improvement of approximately 1,500 basis points q/q and 4,900 points y/y • Awarded 1GW supply agreement with”
Rumble Inc. reported fourth quarter of 2025 results: revenue $27.1 million, net income $32.7 million.
“● Revenue for the fourth quarter was $27.1 million, a sequential increase of 9% from $24.8 million in the third quarter of 2025. ● Average global Monthly Active Users (“MAUs”) of 52 million in the fourth quarter of 2025, a sequential increase of 11% from the third quarter of 2025. The increase is primarily related to an initial investment in international expansion. ● Average Revenue Per User (“ARPU”) for the fourth quarter of 2025 was $0.46, representing a 2% increase from the third quarter of 2025. ● Net Loss for the fourth quarter was $32.7 million compared to a loss of $236.8 million in the fourth quarter of 2024, principally attributable to a $184.7 million loss in the change in fair value of derivative expense related to Tether’s strategic investment in Rumble in the fourth quarter of 2024.”
Invivyd, Inc. reported financial results for the fiscal year ended December 31, 2025.
“Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.”
Invivyd, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $17.2 million.
“Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter”
Marvell Technology, Inc. reported the first quarter of fiscal 2027 results: revenue $2.400 billion +/- 5%, EPS $0.31 +/- $0.05 per share. Guidance initiated.
“other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing. On March 5, 2026, Marvell Technology, Inc. (“Marvell”) issued a press release reporting its financial results for the fourth fiscal quarter and fiscal year 2026 ended January 31, 2026. A copy”
Marvell Technology, Inc. reported fiscal year 2026 ended January 31, 2026 results: revenue $8.195 billion, net income $2.670 billion, EPS $3.07 per diluted share.
“Net revenue for fiscal 2026 was $8.195 billion, a new record. GAAP net income for fiscal 2026 was $2.670 billion, or $3.07 per diluted share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.